comprehensive -WSS

comprehensive

author：knowledge 2025-10-03 00:03:39 - browse：38146

Sammy Kimball for STAT

Can unicorns survive without data? Did biotech get over its skis? And what is going on at Biogen?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, billed as “Moderna 2.0,” ran into behind-the-scenes problems with its scientific data. We also discuss how Biogen’s boardroom scandal has roiled a company that was supposed to be entering a new era.

For more on what we cover, here’s the Laronde story; here’s the latest on Biogen; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Drug repurposing or repositioning? The language matters
Next article： Does Paxlovid work in people vaccinated against Covid

WSS

A $475,000 price tag for a new cancer drug: crazy or meh?

In shift, Texas to cover initial consult for Afghan baby's gene therapy

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

The real point of Kenneth Smith’s execution by nitrogen gas

Do digital therapeutics have a future in medicine?

At JPM 2024, hospital systems pitch financial strength to investors

knowledge

comprehensive

leisure time

State Dept. review finds Biden bears some blame for Afghanistan failures

Does Paxlovid work in people vaccinated against Covid

How to save PrEP access — and even expand it

Some dementia cases could be undiagnosed liver disease

Tori Bowie and the unacceptable rates of Black maternal death

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Anesthesiologist group: stop taking Ozempic before surgery

Vertigo drug brings hope for rare neuron disorder, Niemann

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

focus

Biden administration opens offers in Medicare drug price negotiations

Merck to acquire Harpoon Therapeutics for $680 million

Nonprofit, backed by Microsoft, to certify AI tools in health care

Profiling embryos to choose those with higher IQs is almost a reality

Merck to acquire Harpoon Therapeutics for $680 million

Profiling embryos to choose those with higher IQs is almost a reality

leisure time

focus

focus

focus